Revolution Medicines Insider Files Rule 144 to Sell 13,236 Shares

Rhea-AI Filing Summary

Revolution Medicines (RVMD) Form 144 reports a proposed sale of 13,236 shares of common stock through ETRADE with an aggregate market value of $616,135.80, scheduled approximately on 09/15/2025 and to be executed on Nasdaq. The filing lists four prior restricted stock unit grants acquired on 03/01/2022, 03/01/2023, 03/01/2024 and 03/01/2025 totaling 13,136 shares received for services. It also discloses a sale by the same person on 06/16/2025 of 13,496 shares for gross proceeds of $537,545.68. The filer certifies no undisclosed material information.

Positive

• Disclosure compliance: The filer provides a complete Rule 144 notice including broker, dates, and acquisition history
• Source of shares transparent: Shares originate from restricted stock unit grants issued for services

Negative

• Insider selling activity: A proposed sale of 13,236 shares and a prior sale of 13,496 shares indicate insider monetization
• Market impact risk: Aggregate sale values ($616,135.80 planned; $537,545.68 realized) could exert selling pressure depending on trading liquidity

Insights

Securities Analyst

TL;DR Insider selling disclosed: planned 13,236-share sale valued at $616k and a recent 13,496-share sale for $537.5k.

The filing documents routine insider disposition under Rule 144 rather than an open-market company announcement. The sales stem from restricted stock unit grants received over four years for services, indicating these shares are now eligible for sale. The aggregate values and timing are material for monitoring short-term insider liquidity but do not by themselves disclose company operational changes.

Corporate Governance Expert

TL;DR This is a standard Form 144 disclosure of planned insider sales tied to vested RSUs, with an earlier recent sale noted.

From a governance perspective, the filing meets Rule 144 notice requirements by identifying the broker, planned sale date, and provenance of the shares (RSU grants). The prior June sale and the scheduled September sale suggest ongoing monetization of compensation equity; investors may view repeated sales neutrally unless accompanied by other adverse disclosures. The filer also affirms no material nonpublic information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	13236	616135.80	186933190	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			3481	03/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			3481	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			3013	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			3261	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark A. Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2025	13496	537545.68

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Revolution Medicines (RVMD) Form 144 disclose?

The filing discloses a proposed sale of 13,236 common shares valued at $616,135.80 via ETRADE, with a prior sale on 06/16/2025 of 13,496 shares for $537,545.68.

Who is the broker handling the proposed RVMD share sale?

The broker named is ETRADE Financial Corporation, 3 Edison Drive, Alpharetta GA.

When were the shares being sold originally acquired?

The shares were acquired through restricted stock unit grants on 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025.

What is the planned approximate sale date in the Form 144?

The approximate date of sale is listed as 09/15/2025.

Did the filer confirm possession of material nonpublic information?

Yes. By signing the notice, the person represents they do not know any material adverse information that has not been publicly disclosed.